Efficacy of etifoxine compared to lorazepam monotherapy in the treatment of patients with adjustment disorders with anxiety: a double-blind controlled study in general practice - PubMed (original) (raw)
Clinical Trial
doi: 10.1002/hup.757.
Affiliations
- PMID: 16625522
- DOI: 10.1002/hup.757
Clinical Trial
Efficacy of etifoxine compared to lorazepam monotherapy in the treatment of patients with adjustment disorders with anxiety: a double-blind controlled study in general practice
N Nguyen et al. Hum Psychopharmacol. 2006 Apr.
Erratum in
- Hum Psychopharmacol. 2006 Dec;21(8):562
Abstract
Adjustment Disorders With Anxiety (ADWA) account for almost 10% of psychologically motivated consultations in primary care. The aim of this double-blind randomised parallel group study was to compare (non-inferiority test) the efficacies of etifoxine, a non-benzodiazepine anxiolytic drug, and lorazepam, a benzodiazepine, for ADWA outpatients followed by general practitioners. 191 outpatients (mean age: 43, female: 66%) were assigned to receive etifoxine (50 mg tid) or lorazepam (0.5-0.5-1 mg /day) for 28 days. Efficacy was evaluated on days 7 and 28 of the treatment. The main efficacy assessment criterion was the Hamilton Rating Scale for Anxiety score (HAM-A) on Day 28 adjusted to Day 0. The anxiolytic effect of etifoxine was found not inferior to that of lorazepam (HAM-A score decrease: 54.6% vs 52.3%, respectively, p=0.0006). The two drugs were equivalent on Day 28. However, more etifoxine recipients responded to the treatment (HAM-A score decreased by >or=50%, p=0.03). Clinical improvement (based on Clinical Global Impression scale CGI, Social Adjustment Scale Self-Report SAS-SR, and Sheehan scores) was observed in both treatment arms, but more etifoxine patients improved markedly (p=0.03) and had a marked therapeutic effect without side effects as assessed by CGI, p=0.04. Moreover, 1 week after stopping treatment, fewer patients taking etifoxine experienced a rebound of anxiety, compared to lorazepam (1 and 8, respectively, p=0.034).
Copyright (c) 2006 John Wiley & Sons, Ltd.
Similar articles
- A double-blind, placebo-controlled study comparing the efficacy and safety of ipsapirone versus lorazepam in patients with generalized anxiety disorder: a prospective multicenter trial.
Cutler NR, Sramek JJ, Keppel Hesselink JM, Krol A, Roeschen J, Rickels K, Schweizer E. Cutler NR, et al. J Clin Psychopharmacol. 1993 Dec;13(6):429-37. J Clin Psychopharmacol. 1993. PMID: 7907097 Clinical Trial. - [Comparison of 6 different methods for lorazepam withdrawal. A controlled study, hydroxyzine versus placebo].
Lemoine P, Touchon J, Billardon M. Lemoine P, et al. Encephale. 1997 Jul-Aug;23(4):290-9. Encephale. 1997. PMID: 9417395 Clinical Trial. French. - Etifoxine versus alprazolam for the treatment of adjustment disorder with anxiety: a randomized controlled trial.
Stein DJ. Stein DJ. Adv Ther. 2015 Jan;32(1):57-68. doi: 10.1007/s12325-015-0176-6. Epub 2015 Jan 27. Adv Ther. 2015. PMID: 25620535 Free PMC article. Clinical Trial. - Studies with alpidem in normal volunteers and anxious patients.
Morton S, Lader M. Morton S, et al. Pharmacopsychiatry. 1990 May;23 Suppl 3:120-3. doi: 10.1055/s-2007-1014547. Pharmacopsychiatry. 1990. PMID: 1974071 Review. - Clinical methodology for testing of anxiolytic drugs.
Bourin M. Bourin M. Therapie. 2000 Jan-Feb;55(1):147-53. Therapie. 2000. PMID: 10860018 Review.
Cited by
- Local and global effects of sedation in resting-state fMRI: a randomized, placebo-controlled comparison between etifoxine and alprazolam.
Wein S, Riebel M, Seidel P, Brunner LM, Wagner V, Nothdurfter C, Rupprecht R, Schwarzbach JV. Wein S, et al. Neuropsychopharmacology. 2024 Oct;49(11):1738-1748. doi: 10.1038/s41386-024-01884-5. Epub 2024 May 31. Neuropsychopharmacology. 2024. PMID: 38822128 Free PMC article. Clinical Trial. - The translocator protein 18kDa ligand etifoxine in the treatment of depressive disorders-a double-blind, randomized, placebo-controlled proof-of-concept study.
Brunner LM, Riebel M, Wein S, Koller M, Zeman F, Huppertz G, Emmer T, Eberhardt Y, Schwarzbach J, Rupprecht R, Nothdurfter C. Brunner LM, et al. Trials. 2024 Apr 22;25(1):274. doi: 10.1186/s13063-024-08120-x. Trials. 2024. PMID: 38650030 Free PMC article. Clinical Trial. - Minor tranquillizers for short-term treatment of newly onset symptoms of anxiety and distress: a systematic review with network meta-analysis of randomized trials.
Munkholm K, Ussing A, Brink M, Edemann-Callesen H, Canbolat SS, Christensen R, Dahl KS, Ebdrup BH, Jensen MEJ, Kierulf-Lassen C, Madsen GK, Nielsen SM, Paulsen CP, Rohde JF, Tarp S, Baandrup L. Munkholm K, et al. Eur Arch Psychiatry Clin Neurosci. 2024 Apr;274(3):475-486. doi: 10.1007/s00406-023-01680-0. Epub 2023 Aug 25. Eur Arch Psychiatry Clin Neurosci. 2024. PMID: 37624378 Free PMC article. - Translocator protein in the rise and fall of central nervous system neurons.
Cheung G, Lin YC, Papadopoulos V. Cheung G, et al. Front Cell Neurosci. 2023 Jun 21;17:1210205. doi: 10.3389/fncel.2023.1210205. eCollection 2023. Front Cell Neurosci. 2023. PMID: 37416505 Free PMC article. Review. - Neurosteroids and translocator protein 18 kDa (TSPO) in depression: implications for synaptic plasticity, cognition, and treatment options.
Rupprecht R, Pradhan AK, Kufner M, Brunner LM, Nothdurfter C, Wein S, Schwarzbach J, Puig X, Rupprecht C, Rammes G. Rupprecht R, et al. Eur Arch Psychiatry Clin Neurosci. 2023 Oct;273(7):1477-1487. doi: 10.1007/s00406-022-01532-3. Epub 2022 Dec 27. Eur Arch Psychiatry Clin Neurosci. 2023. PMID: 36574032 Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Research Materials